Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)

This measure assesses the percentage of members 18–64 years of age with schizophrenia or schizoaffective disorder and diabetes, who had both an LDL-C test and an HbA1c test during the measurement year.

Why It Matters

An estimated 33.4% of people with schizophrenia have metabolic syndrome—a rate nearly two times higher than that of the general population.¹

Among patients with co-occurring schizophrenia and metabolic disorders, the nontreatment rate for diabetes is approximately 30%.² In addition to general diabetes risk factors, diabetes is promoted in patients with schizophrenia by initial and current treatment with olanzapine and mid-potency first-generation antipsychotics (FGA), as well as by current treatment with low-potency FGAs and clozapine.³

Historical Results – National Averages

This State of Healthcare Quality Report classifies health plans differently than NCQA’s Quality Compass. HMO corresponds to All LOBs (excluding PPO and EPO) within Quality Compass. PPO corresponds to PPO and EPO within Quality Compass.

Figures do not account for changes in the underlying measure that could break trending. Contact Information Products via my.ncqa.org for analysis that accounts for trend breaks.